Literature DB >> 19106539

[A case of successful management of liver metastases of pancreatic carcinoma by hepatectomy and adjuvant chemotherapy].

Shigeru Fujisaki1, Motoi Takashina, Kenichi Sakurai, Ryouichi Tomita, Tadatoshi Takayama.   

Abstract

We have experienced a successful case of liver metastases from pancreatic ductal adenocarcinoma treated by hepatectomy and adjuvant chemotherapy. A 62-year-old male had undergone pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Thirty days after the surgery, he was given a systemic administration of gemcitabine (GEM) at a dose of 1,000-1,400 mg/body biweekly. Serum CA19-9 was elevated about 8 months after the primary resection. In addition, abdominal CT scan revealed a hepatic metastatic lesion about 10 month after the surgery, We changed the protocol of the chemotherapy to a systemic administration of GEM at a dose of 1,200-1,400 mg/body once a week for 3 weeks with a 1-week rest. Serum CA19-9 was more elevated, so he underwent hepatectomy for liver metastases from pancreatic ductal adenocarcinoma 13 months after the primary surgery, and the adjuvant chemotherapy of GEM restarted at 21 days after the hepatectomy. He has survived without recurrence more than 14 months after the hepatectomy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19106539

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

1.  The global impact of endoscopic ultrasound (EUS) regarding the survival of a pancreatic adenocarcinoma in a tertiary hospital.

Authors:  Jose Luis Ulla-Rocha; Angel Alvarez-Prechous; Javier Paz-Esquete; Carlos Alvarez Alvarez; Pedro Lopez-Clemente; Elias Dominguez-Comesaña; Enrique Vazquez-Astray
Journal:  J Gastrointest Cancer       Date:  2010-09

2.  Long-term survival following hepatectomy, radiation, and chemotherapy for recurrent pancreatic carcinoma: a case report.

Authors:  Shigeru Fujisaki; Motoi Takashina; Ryouichi Tomita; Kenichi Sakurai; Tadatoshi Takayama
Journal:  World J Surg Oncol       Date:  2017-08-23       Impact factor: 2.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.